mProX™ Human LILRB3 Stable Cell Line

Product Information

Target Family

Oncology

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;Molm13

Target Classification

Oncology Cell Lines

Target Research Area

CNS Research

Related Diseases

Anencephaly; Takayasu Arteritis

Gene ID

Human:11025

UniProt ID

Human:C9JWL8

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

LILRB3, also known as leukocyte immunoglobulin-like receptor B3, has various applications in different fields. In the context of glioma, LILRB3 has been found to suppress immunity and is associated with poor prognosis. In a study on immune-associated mRNA expression, LILRB3 was one of the mRNAs found to be increased after Baker's yeast beta glucan supplementation, which supports the immune system and reduces susceptibility to infection. In the study of tropical pulmonary eosinophilia, LILRB3 was identified as one of the negative regulators of the immune response, playing a role in promoting lung damage. In a case of diffuse large B-cell lymphoma, LILRB3 was expressed in tumor-associated macrophages and was associated with poor prognosis. Additionally, LILRB3 has been identified as a putative cell surface receptor of APOE4, one of the isoforms of apolipoprotein E, and its interaction with APOE4 activates microglia cells into a pro-inflammatory state. These findings suggest that LILRB3 has implications in immune regulation, cancer prognosis, and neuroinflammation.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human LILRB3 Stable Cell Line (S01YF-1023-PY237). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Cameron Jones (Verified Customer)

How does LILRB3 affect acute myeloid leukemia development? Nov 25 2021

chat Patrick Liam (Creative Biolabs Scientific Support)

LILRB3 modulates acute myeloid leukemia (AML) cell survival and antileukemic T-cell responses through the TRAF2-cFLIP-NF-κB signaling axis, indicating its role in AML progression and immune evasion. Nov 25 2021

chat Skyler Garcia (Verified Customer)

What is the role of LILRB3 in epithelial cell behavior? Jan 19 2021

chat Patrick Liam (Creative Biolabs Scientific Support)

LILRB3 expressed on non-transformed epithelial cells recognizes MHC class I on transformed cells, triggering their extrusion, which is a mechanism for removing precancerous cells. Jan 19 2021

Published Data

Fig.1 An increase in sensitivity to cytotoxic T cells is induced in monocytic AML cells by LILRB3.

Four days after the transplantation of Molm13 AML cells into NSG mice, injection of T cells was performed. In the presence of T cells, a significantly slower development of Molm13 AML cells silenced for LILRB3 was observed compared to AML cells expressing the control shRNA.

Ref: Wu, Guojin, et al. "LILRB3 supports acute myeloid leukemia development and regulates T-cell antitumor immune responses through the TRAF2-cFLIP-NF-κB signaling axis." Nature cancer 2.11 (2021): 1170-1184.

Pubmed: 35122056

DOI: 10.1038/s43018-021-00262-0

Research Highlights

Zhuang, Qiyuan. et al. "LILRB3 suppresses immunity in glioma and is associated with poor prognosis." Clinical and translational medicine, 2023.
This article is a research letter that reports the findings of a study on LILRB3, a protein that suppresses immunity in glioma, a type of brain tumor. The authors show that LILRB3 is highly expressed in monocyte-derived macrophages, a type of immune cell, and is associated with poor prognosis and mesenchymal-like cellular state in glioma. They also demonstrate that LILRB3 binds with APOE, a lipid carrier, and activates SHP-1, an enzyme that inhibits immune signaling. They suggest that LILRB3 could be a potential target for immunotherapy.
Zhuang, Qiyuan. et al. "LILRB3 suppresses immunity in glioma and is associated with poor prognosis." Clinical and translational medicine, 2023.
Pubmed: 37830127 DOI: 10.1002/ctm2.1396

K McFarlin, Brian. et al. "Dry blood spot samples to monitor immune-associated mRNA expression in intervention studies: Impact of Baker's yeast beta glucan." Methods (San Diego, Calif.), 2023.
In this study, the researchers aimed to determine the efficacy of a new dry blood spot (DBS) method in measuring the immunological response to physical stressors, specifically focusing on the effect of Baker's Yeast Beta Glucan (BYBG) supplementation on post-exercise mRNA expression. DBS samples were collected from participants before and after a 90-minute run/walk trial in a hot, humid environment. Total RNA was extracted and analyzed using a 574-plex Human Immunology mRNA panel. The results showed that BYBG supplementation led to increased expression of 12 mRNAs and decreased expression of 4 mRNAs across all post-exercise time points. Furthermore, eleven immune-response pathways were found to be significantly enriched by BYBG supplementation. This study demonstrates the potential of DBS sampling for monitoring immune biomarkers in intervention studies, specifically showing that BYBG supplementation can enhance immune system function and decrease susceptibility to opportunistic infection after physical stress. Further studies may utilize this approach for assessing other nutritional, health, or medical interventions. The findings of this study highlight the usefulness of DBS methodology in field settings where traditional blood collection methods may be challenging.
K McFarlin, Brian. et al. "Dry blood spot samples to monitor immune-associated mRNA expression in intervention studies: Impact of Baker's yeast beta glucan." Methods (San Diego, Calif.), 2023.
Pubmed: 37741562 DOI: 10.1016/j.ymeth.2023.09.006